HomeAlzamend Neuro, Inc.

Trade Alzamend Neuro, Inc. - ALZN CFD

1.1185-12.5%
The chart shows the ALZN stock price data over the last 1 day, with a current price of 1.1515, a high of 1.2184, and a low of 1.1085.
Low: 1.1085High: 1.2184
Sellers:
0%
Buyers:
100%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.033
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02226 %
(-$2.23)

Trade size with leverage ~ $10,000.00

Money from leverage ~ $$9,000.00


-0.02226%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00004 %
($0.00)

Trade size with leverage ~ $10,000.00

Money from leverage ~ $$9,000.00


0.00004%
Overnight funding adjustment time22:00 (UTC)
CurrencyUSD
Min traded quantity10
Margin10.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close1.2783
Open1.2184
1-Year Change-44.49%
Day's Range1.1085 - 1.2184

Trade Alzamend Neuro, Inc. - ALZN

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company''s lead product candidate is AL001 for the treatment of Alzheimer''s and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient''s immunological system to Alzheimer''s. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready